P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000971144.30344.9c |
| _version_ | 1797281640150466560 |
|---|---|
| author | Francesca Palandri Lucia Masarova Srdan Verstovsek Ruben Mesa Claire Harrison Gautam Sajeev Boris Gorsh Ryan Simpson Sang Cho Zhaohui Wang Catherine Ellis Sean Conlon James Signorovitch |
| author_facet | Francesca Palandri Lucia Masarova Srdan Verstovsek Ruben Mesa Claire Harrison Gautam Sajeev Boris Gorsh Ryan Simpson Sang Cho Zhaohui Wang Catherine Ellis Sean Conlon James Signorovitch |
| author_sort | Francesca Palandri |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:00:21Z |
| format | Article |
| id | doaj.art-c10c24e0a2514a8facb9fec41ae8ad42 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:00:21Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-c10c24e0a2514a8facb9fec41ae8ad422024-03-03T03:25:28ZengWileyHemaSphere2572-92412023-08-017e303449c10.1097/01.HS9.0000971144.30344.9c202308003-00960P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSISFrancesca Palandri0Lucia Masarova1Srdan Verstovsek2Ruben Mesa3Claire Harrison4Gautam Sajeev5Boris Gorsh6Ryan Simpson7Sang Cho8Zhaohui Wang9Catherine Ellis10Sean Conlon11James Signorovitch121 Universita Di Bologna, Bologna, Italy2 The University of Texas MD Anderson Cancer Center, Houston, United States2 The University of Texas MD Anderson Cancer Center, Houston, United States3 Wake Health, Winston-Salem, United States4 Guys and St Thomas’ NHS Foundation Trust, London, United Kingdom5 Analysis Group, Boston, United States6 GSK plc, Philadelphia, United States5 Analysis Group, Boston, United States5 Analysis Group, Boston, United States6 GSK plc, Philadelphia, United States6 GSK plc, Philadelphia, United States7 GSK plc, Reading, United Kingdom5 Analysis Group, Boston, United Stateshttp://journals.lww.com/10.1097/01.HS9.0000971144.30344.9c |
| spellingShingle | Francesca Palandri Lucia Masarova Srdan Verstovsek Ruben Mesa Claire Harrison Gautam Sajeev Boris Gorsh Ryan Simpson Sang Cho Zhaohui Wang Catherine Ellis Sean Conlon James Signorovitch P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS HemaSphere |
| title | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_full | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_fullStr | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_full_unstemmed | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_short | P1062: INDIRECT TREATMENT COMPARISON OF MOMELOTINIB VS FEDRATINIB SAFETY IN PATIENTS WITH MYELOFIBROSIS |
| title_sort | p1062 indirect treatment comparison of momelotinib vs fedratinib safety in patients with myelofibrosis |
| url | http://journals.lww.com/10.1097/01.HS9.0000971144.30344.9c |
| work_keys_str_mv | AT francescapalandri p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT luciamasarova p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT srdanverstovsek p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT rubenmesa p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT claireharrison p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT gautamsajeev p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT borisgorsh p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT ryansimpson p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT sangcho p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT zhaohuiwang p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT catherineellis p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT seanconlon p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis AT jamessignorovitch p1062indirecttreatmentcomparisonofmomelotinibvsfedratinibsafetyinpatientswithmyelofibrosis |